Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1949 1
1950 1
1951 1
1952 2
1953 10
1954 4
1956 2
1957 5
1958 6
1959 3
1961 3
1962 9
1963 4
1964 15
1965 13
1966 24
1967 22
1968 28
1969 16
1970 14
1971 19
1972 21
1973 13
1974 22
1975 17
1976 22
1977 19
1978 25
1979 24
1980 45
1981 38
1982 47
1983 36
1984 50
1985 38
1986 54
1987 60
1988 48
1989 61
1990 69
1991 80
1992 89
1993 99
1994 103
1995 108
1996 121
1997 120
1998 104
1999 95
2000 97
2001 94
2002 120
2003 101
2004 113
2005 134
2006 121
2007 101
2008 129
2009 145
2010 148
2011 168
2012 187
2013 201
2014 186
2015 218
2016 193
2017 196
2018 219
2019 221
2020 273
2021 324
2022 320
2023 34
Text availability
Article attribute
Article type
Publication date

Search Results

5,401 results
Results by year
Filters applied: . Clear all
Page 1
Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2.
Takashita E, Kinoshita N, Yamayoshi S, Sakai-Tagawa Y, Fujisaki S, Ito M, Iwatsuki-Horimoto K, Halfmann P, Watanabe S, Maeda K, Imai M, Mitsuya H, Ohmagari N, Takeda M, Hasegawa H, Kawaoka Y. Takashita E, et al. Among authors: maeda k. N Engl J Med. 2022 Apr 14;386(15):1475-1477. doi: 10.1056/NEJMc2201933. Epub 2022 Mar 9. N Engl J Med. 2022. PMID: 35263535 Free PMC article. No abstract available.
Characterization and antiviral susceptibility of SARS-CoV-2 Omicron/BA.2.
Kawaoka Y, Uraki R, Kiso M, Iida S, Imai M, Takashita E, Kuroda M, Halfmann P, Loeber S, Maemura T, Yamayoshi S, Fujisaki S, Wang Z, Ito M, Ujie M, Iwatsuki-Horimoto K, Furusawa Y, Wright R, Chong Z, Ozono S, Yasuhara A, Ueki H, Sakai Y, Li R, Liu Y, Larson D, Koga M, Tsutsumi T, Adachi E, Saito M, Yamamoto S, Matsubara S, Hagihara M, Mitamura K, Sato T, Hojo M, Hattori SI, Maeda K, Okuda M, Murakami J, Duong C, Godbole S, Douek D, Watanabe S, Ohmagari N, Yotsuyanagi H, Diamond M, Hasegawa H, Mitsuya H, Suzuki T. Kawaoka Y, et al. Among authors: maeda k. Res Sq. 2022 Feb 24:rs.3.rs-1375091. doi: 10.21203/rs.3.rs-1375091/v1. Preprint. Res Sq. 2022. PMID: 35233565 Free PMC article. Updated.
Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant.
Takashita E, Kinoshita N, Yamayoshi S, Sakai-Tagawa Y, Fujisaki S, Ito M, Iwatsuki-Horimoto K, Chiba S, Halfmann P, Nagai H, Saito M, Adachi E, Sullivan D, Pekosz A, Watanabe S, Maeda K, Imai M, Yotsuyanagi H, Mitsuya H, Ohmagari N, Takeda M, Hasegawa H, Kawaoka Y. Takashita E, et al. Among authors: maeda k. N Engl J Med. 2022 Mar 10;386(10):995-998. doi: 10.1056/NEJMc2119407. Epub 2022 Jan 26. N Engl J Med. 2022. PMID: 35081300 Free PMC article. No abstract available.
Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2.
Uraki R, Kiso M, Iida S, Imai M, Takashita E, Kuroda M, Halfmann PJ, Loeber S, Maemura T, Yamayoshi S, Fujisaki S, Wang Z, Ito M, Ujie M, Iwatsuki-Horimoto K, Furusawa Y, Wright R, Chong Z, Ozono S, Yasuhara A, Ueki H, Sakai-Tagawa Y, Li R, Liu Y, Larson D, Koga M, Tsutsumi T, Adachi E, Saito M, Yamamoto S, Hagihara M, Mitamura K, Sato T, Hojo M, Hattori SI, Maeda K, Valdez R; IASO study team; Okuda M, Murakami J, Duong C, Godbole S, Douek DC, Maeda K, Watanabe S, Gordon A, Ohmagari N, Yotsuyanagi H, Diamond MS, Hasegawa H, Mitsuya H, Suzuki T, Kawaoka Y. Uraki R, et al. Among authors: maeda k. Nature. 2022 Jul;607(7917):119-127. doi: 10.1038/s41586-022-04856-1. Epub 2022 May 16. Nature. 2022. PMID: 35576972
SAPHO syndrome and pustulotic arthro-osteitis.
Kishimoto M, Taniguchi Y, Tsuji S, Ishihara Y, Deshpande GA, Maeda K, Okada M, Komagata Y, Kobayashi S, Okubo Y, Tomita T, Kaname S. Kishimoto M, et al. Among authors: maeda k. Mod Rheumatol. 2022 Jul 1;32(4):665-674. doi: 10.1093/mr/roab103. Mod Rheumatol. 2022. PMID: 34967407 Review.
Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants.
Takashita E, Yamayoshi S, Simon V, van Bakel H, Sordillo EM, Pekosz A, Fukushi S, Suzuki T, Maeda K, Halfmann P, Sakai-Tagawa Y, Ito M, Watanabe S, Imai M, Hasegawa H, Kawaoka Y. Takashita E, et al. Among authors: maeda k. N Engl J Med. 2022 Aug 4;387(5):468-470. doi: 10.1056/NEJMc2207519. Epub 2022 Jul 20. N Engl J Med. 2022. PMID: 35857646 Free PMC article. No abstract available.
Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB.
Imai M, Ito M, Kiso M, Yamayoshi S, Uraki R, Fukushi S, Watanabe S, Suzuki T, Maeda K, Sakai-Tagawa Y, Iwatsuki-Horimoto K, Halfmann PJ, Kawaoka Y. Imai M, et al. Among authors: maeda k. N Engl J Med. 2023 Jan 5;388(1):89-91. doi: 10.1056/NEJMc2214302. Epub 2022 Dec 7. N Engl J Med. 2023. PMID: 36476720 Free PMC article. No abstract available.
Control of RNA Stability in Immunity.
Akira S, Maeda K. Akira S, et al. Among authors: maeda k. Annu Rev Immunol. 2021 Apr 26;39:481-509. doi: 10.1146/annurev-immunol-101819-075147. Epub 2021 Feb 12. Annu Rev Immunol. 2021. PMID: 33577347
5,401 results